Lilly(US:LLY) Yahoo Finance·2025-11-03 03:10Core Insights - Eli Lilly & Company (NYSE: LLY) is recognized for its strong earnings growth potential over the next five years, with Cantor Fitzgerald maintaining an Overweight rating and a price target of $925 following the exclusion of its oral GLP-1 treatment, orforglipron, from the initial group of medications eligible for Commissioner's National Priority Vouchers (CNPV) [1][2] Group 1 - Eli Lilly's stock faced pressure in after-hours trading due to speculation regarding the potential CNPV for orforglipron and overly optimistic expectations for approval by the end of 2025 [2] - The news regarding orforglipron coincided with ambiguous and sometimes contradictory commentary on GLP-1 pricing, particularly related to ongoing negotiations over semaglutide pricing under the Inflation Reduction Act, which could potentially be as low as $150 per month [2] - Eli Lilly is a major global pharmaceutical company, established in 1876, and has become one of the largest pharmaceutical firms worldwide, involved in the development, manufacturing, and distribution of a diverse range of drugs [3]